OPKO Health Releases Q2 2025 Business Highlights and Financial Results

OPKO Health, Inc. reports on its recent business highlights and financial results for the second quarter of 2025. Among the significant developments during this period, Merck has made progress with an investigational vaccine for the Epstein-Barr virus. This vaccine is currently in a Phase 1 trial to evaluate its safety and tolerability in healthy adults, with plans for potential Phase 2 studies based on the outcomes.

In the field of immuno-oncology and immunology, ModeX has advanced four potential clinical candidates in its portfolio. The MDX2001 CMet-Trop2/CD3-CD28 tetraspecific antibody has reached the fifth dose level in its Phase 1 trial and is expected to move into Phase 1b studies for selected solid tumors in 2026. Additionally, MDX2004, a multispecific immune rejuvenator, is anticipated to enter clinical trials later this year, and the MDX2003 tetraspecific antibody targeting lymphoma/leukemia is slated to begin human trials in early 2026. ModeX is also progressing the development of multispecific antibodies for immune-compromised patients at risk for COVID and influenza, supported by the Biomedical Advanced Research and Development Authority (BARDA).

At the American Diabetes Association 85th Scientific Sessions in June, OPKO presented preclinical data on its novel long-acting glucagon-like peptide-1 receptor/glucagon receptor dual agonist, OPK-88006. This compound showed encouraging results in disease models of obesity and energy expenditure activities, particularly in a study involving a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). OPK-88006 demonstrated superior therapeutic benefits compared to other treatments, positioning it as a potential treatment for MASH. Moreover, an abstract on OPK-88006 as a first-in-class dual GLP-1/glucagon tablet for patients with obesity and metabolic disorders was selected for presentation at the ENDO 2025 annual meeting.

Another abstract was selected for the 2025 ESPEN Congress, focusing on the pharmacokinetics/pharmacodynamics of an oral GLP-2 tablet for the treatment of short bowel syndrome. The presentation will shed light on the potential of this tablet in managing this gastrointestinal condition.

In conclusion, OPKO Health continues to make significant strides in advancing innovative therapies and treatments across various medical fields, reflecting its commitment to improving patient outcomes and addressing unmet medical needs. These recent developments underscore the company’s dedication to research and scientific advancements towards better healthcare solutions.